Abstract
The objective of this prospective randomized phase III trial was to compare paclitaxel plus carboplatin (PC) versus topotecan plus carboplatin and paclitaxel (TPC) in women with suboptimal stage III (residual tumour >1cm) or stage IV ovarian cancer to evaluate the survival rate and toxicities.
Lingua originale | English |
---|---|
pagine (da-a) | 2905-2912 |
Numero di pagine | 8 |
Rivista | European journal of cancer (Oxford, England : 1990) |
Volume | 46 |
DOI | |
Stato di pubblicazione | Pubblicato - 2010 |
Keywords
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
- Carboplatin
- Disease-Free Survival
- Female
- Humans
- Kaplan-Meier Estimate
- Middle Aged
- Ovarian Neoplasms
- Paclitaxel
- Topotecan
- Treatment Outcome
- Young Adult